Learning Objectives
Metabolic Abnormalities Associated With T2D
CV Events With PPAR-gamma Agonists
Effect of Fibrates on CV OutcomesA Systematic Review and Meta-analysis
ACCORD Lipid Hazard Ratios for the Primary Outcome
Pioglitazone Meta-analysisHeart Failure & MI
Dual PPAR a/g Agonists
AleCardioAleglitazar (PPAR a/g Agonist) in Patients With T2D and ACS
AleCardio Efficacy and Safety Outcomes
AleCardioGlycemic Control and Lipoprotein Effects
Genes Regulated by Glitazones
Older Antidiabetic Drugs and CV Benefit/Harm
SAVOR-TIMI 53Clinical End Points: Saxagliptin (DPP4 Inhibitor) vs Placebo
SAVOR-TIMI 53Hospitalization for Heart Failure Stratified by NT-
proBNP Quartiles
SAVOR-TIMI 53Safety Endpoints
EXAMINESafety End Points: Alogliptin (DPP4 Inhibitor) vs Placebo
EXAMINEHeart Failure Outcomes
Mechanism of Heart Failure
Ongoing CVD Outcomes Trials in Type 2 Diabetes
Clinical Trial Design Considerations
AlePreventAleglitazar in Patients With Stable CVD and
Glucose Abnormalities
Newer Antidiabetic Drugs & CV Risk Reduction
Concluding Remarks
Abbreviations (cont)
Abbreviations (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)